Enzyme replacement therapy for alpha-mannosidosis: 12 months follow-up of a single centre, randomised, multiple dose study

Line Gutte Borgwardt; Christine I. Dali; J Fogh; Joan Månsson; K J Olsen; Hans Christian Beck; K G Nielsen; L H Nielsen; S O E Olsen; H M F Riise Stensland; O Nilssen; F Wibrand; Anne-Marie Thuesen; T Pearl; U Haugsted; P Saftig; J Blanz; Sheila Jones; A Tylki-Szymanska; N Guffon-Fouiloux; Marie Valentin Beck; A M Lund

doi:10.1007/s10545-013-9595-1

Enzyme replacement therapy for alpha-mannosidosis: 12 months follow-up of a single centre, randomised, multiple dose study

Line Gutte Borgwardt, Christine I. Dali, J Fogh, Joan Månsson, K J Olsen, Hans Christian Beck, K G Nielsen, L H Nielsen, S O E Olsen, H M F Riise Stensland, O Nilssen, F Wibrand, Anne-Marie Thuesen, T Pearl, U Haugsted, P Saftig, J Blanz, Sheila Jones, A Tylki-Szymanska, N Guffon-FouilouxMarie Valentin Beck, A M Lund

27 Citations (Scopus)

Abstract

Background: Alpha-mannosidosis (OMIM 248500) is a rare lysosomal storage disease (LSD) caused by alpha-mannosidase deficiency. Manifestations include intellectual disabilities, facial characteristics and hearing impairment. A recombinant human alpha-mannosidase (rhLAMAN) has been developed for weekly intravenous enzyme replacement therapy (ERT). We present the preliminary data after 12 months of treatment. Methods: This is a phase I-II study to evaluate safety and efficacy of rhLAMAN. Ten patients (7-17 y) were treated. We investigated efficacy by testing motor function (6-minutes-Walk-Test (6-MWT), 3-min-Stair-Climb-Test (3-MSCT), The Bruininks-Oseretsky Test of Motor Proficiency (BOT2), cognitive function (Leiter-R), oligosaccharides in serum, urine and CSF and Tau- and GFA-protein in CSF. Results: Oligosaccharides: S-, U- and CSF-oligosaccharides decreased 88.6 % (CI -92.0 -85.2, p < 0.001), 54.1 % (CI -69.5- -38.7, p < 0,001), and 25.7 % (CI -44.3- -7.1, p < 0.05), respectively. Biomarkers: CSF-Tau- and GFA-protein decreased 15 %, p < 0.009) and 32.5, p < 0.001 respectively. Motor function: Improvements in 3MSCT (31 steps (CI 6.8-40.5, p < 0.01) and in 6MWT (60.4 m (CI -8.9 -51.1, NS) were achieved. Cognitive function: Improvement in the total Equivalence Age of 4 months (0.34) was achieved in the Leiter R test (CI -0.2-0.8, NS). Conclusions: These data suggest that rhLAMAN may be an encouraging new treatment for patients with alpha-mannosidosis.The study is designed to continue for a total of 18 months. Longer-term follow-up of patients in this study and the future placebo-controlled phase 3 trial are needed to provide greater support for the findings in this study.

Original language	English
Journal	Journal of Inherited Metabolic Disease
Volume	36
Issue number	6
Pages (from-to)	1015-1024
Number of pages	10
ISSN	0141-8955
DOIs	https://doi.org/10.1007/s10545-013-9595-1
Publication status	Published - Nov 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10545-013-9595-1

Cite this

Borgwardt, L. G., Dali, C. I., Fogh, J., Månsson, J., Olsen, K. J., Beck, H. C., Nielsen, K. G., Nielsen, L. H., Olsen, S. O. E., Riise Stensland, H. M. F., Nilssen, O., Wibrand, F., Thuesen, A.-M., Pearl, T., Haugsted, U., Saftig, P., Blanz, J., Jones, S., Tylki-Szymanska, A., ... Lund, A. M. (2013). Enzyme replacement therapy for alpha-mannosidosis: 12 months follow-up of a single centre, randomised, multiple dose study. Journal of Inherited Metabolic Disease, 36(6), 1015-1024. https://doi.org/10.1007/s10545-013-9595-1

Borgwardt, LG, Dali, CI, Fogh, J, Månsson, J, Olsen, KJ, Beck, HC, Nielsen, KG, Nielsen, LH, Olsen, SOE, Riise Stensland, HMF, Nilssen, O, Wibrand, F, Thuesen, A-M, Pearl, T, Haugsted, U, Saftig, P, Blanz, J, Jones, S, Tylki-Szymanska, A, Guffon-Fouiloux, N, Beck, MV & Lund, AM 2013, 'Enzyme replacement therapy for alpha-mannosidosis: 12 months follow-up of a single centre, randomised, multiple dose study', Journal of Inherited Metabolic Disease, vol. 36, no. 6, pp. 1015-1024. https://doi.org/10.1007/s10545-013-9595-1

@article{19034174b6544b9f8ea1ca8395f82dd6,

title = "Enzyme replacement therapy for alpha-mannosidosis: 12 months follow-up of a single centre, randomised, multiple dose study",

abstract = "Background: Alpha-mannosidosis (OMIM 248500) is a rare lysosomal storage disease (LSD) caused by alpha-mannosidase deficiency. Manifestations include intellectual disabilities, facial characteristics and hearing impairment. A recombinant human alpha-mannosidase (rhLAMAN) has been developed for weekly intravenous enzyme replacement therapy (ERT). We present the preliminary data after 12 months of treatment. Methods: This is a phase I-II study to evaluate safety and efficacy of rhLAMAN. Ten patients (7-17 y) were treated. We investigated efficacy by testing motor function (6-minutes-Walk-Test (6-MWT), 3-min-Stair-Climb-Test (3-MSCT), The Bruininks-Oseretsky Test of Motor Proficiency (BOT2), cognitive function (Leiter-R), oligosaccharides in serum, urine and CSF and Tau- and GFA-protein in CSF. Results: Oligosaccharides: S-, U- and CSF-oligosaccharides decreased 88.6 % (CI -92.0 -85.2, p < 0.001), 54.1 % (CI -69.5- -38.7, p < 0,001), and 25.7 % (CI -44.3- -7.1, p < 0.05), respectively. Biomarkers: CSF-Tau- and GFA-protein decreased 15 %, p < 0.009) and 32.5, p < 0.001 respectively. Motor function: Improvements in 3MSCT (31 steps (CI 6.8-40.5, p < 0.01) and in 6MWT (60.4 m (CI -8.9 -51.1, NS) were achieved. Cognitive function: Improvement in the total Equivalence Age of 4 months (0.34) was achieved in the Leiter R test (CI -0.2-0.8, NS). Conclusions: These data suggest that rhLAMAN may be an encouraging new treatment for patients with alpha-mannosidosis.The study is designed to continue for a total of 18 months. Longer-term follow-up of patients in this study and the future placebo-controlled phase 3 trial are needed to provide greater support for the findings in this study.",

author = "Borgwardt, {Line Gutte} and Dali, {Christine I.} and J Fogh and Joan M{\aa}nsson and Olsen, {K J} and Beck, {Hans Christian} and Nielsen, {K G} and Nielsen, {L H} and Olsen, {S O E} and {Riise Stensland}, {H M F} and O Nilssen and F Wibrand and Anne-Marie Thuesen and T Pearl and U Haugsted and P Saftig and J Blanz and Sheila Jones and A Tylki-Szymanska and N Guffon-Fouiloux and Beck, {Marie Valentin} and Lund, {A M}",

year = "2013",

month = nov,

doi = "10.1007/s10545-013-9595-1",

language = "English",

volume = "36",

pages = "1015--1024",

journal = "Journal of Inherited Metabolic Disease",

issn = "0141-8955",

publisher = "Springer",

number = "6",

}

TY - JOUR

T1 - Enzyme replacement therapy for alpha-mannosidosis

T2 - 12 months follow-up of a single centre, randomised, multiple dose study

AU - Borgwardt, Line Gutte

AU - Dali, Christine I.

AU - Fogh, J

AU - Månsson, Joan

AU - Olsen, K J

AU - Beck, Hans Christian

AU - Nielsen, K G

AU - Nielsen, L H

AU - Olsen, S O E

AU - Riise Stensland, H M F

AU - Nilssen, O

AU - Wibrand, F

AU - Thuesen, Anne-Marie

AU - Pearl, T

AU - Haugsted, U

AU - Saftig, P

AU - Blanz, J

AU - Jones, Sheila

AU - Tylki-Szymanska, A

AU - Guffon-Fouiloux, N

AU - Beck, Marie Valentin

AU - Lund, A M

PY - 2013/11

Y1 - 2013/11

N2 - Background: Alpha-mannosidosis (OMIM 248500) is a rare lysosomal storage disease (LSD) caused by alpha-mannosidase deficiency. Manifestations include intellectual disabilities, facial characteristics and hearing impairment. A recombinant human alpha-mannosidase (rhLAMAN) has been developed for weekly intravenous enzyme replacement therapy (ERT). We present the preliminary data after 12 months of treatment. Methods: This is a phase I-II study to evaluate safety and efficacy of rhLAMAN. Ten patients (7-17 y) were treated. We investigated efficacy by testing motor function (6-minutes-Walk-Test (6-MWT), 3-min-Stair-Climb-Test (3-MSCT), The Bruininks-Oseretsky Test of Motor Proficiency (BOT2), cognitive function (Leiter-R), oligosaccharides in serum, urine and CSF and Tau- and GFA-protein in CSF. Results: Oligosaccharides: S-, U- and CSF-oligosaccharides decreased 88.6 % (CI -92.0 -85.2, p < 0.001), 54.1 % (CI -69.5- -38.7, p < 0,001), and 25.7 % (CI -44.3- -7.1, p < 0.05), respectively. Biomarkers: CSF-Tau- and GFA-protein decreased 15 %, p < 0.009) and 32.5, p < 0.001 respectively. Motor function: Improvements in 3MSCT (31 steps (CI 6.8-40.5, p < 0.01) and in 6MWT (60.4 m (CI -8.9 -51.1, NS) were achieved. Cognitive function: Improvement in the total Equivalence Age of 4 months (0.34) was achieved in the Leiter R test (CI -0.2-0.8, NS). Conclusions: These data suggest that rhLAMAN may be an encouraging new treatment for patients with alpha-mannosidosis.The study is designed to continue for a total of 18 months. Longer-term follow-up of patients in this study and the future placebo-controlled phase 3 trial are needed to provide greater support for the findings in this study.

AB - Background: Alpha-mannosidosis (OMIM 248500) is a rare lysosomal storage disease (LSD) caused by alpha-mannosidase deficiency. Manifestations include intellectual disabilities, facial characteristics and hearing impairment. A recombinant human alpha-mannosidase (rhLAMAN) has been developed for weekly intravenous enzyme replacement therapy (ERT). We present the preliminary data after 12 months of treatment. Methods: This is a phase I-II study to evaluate safety and efficacy of rhLAMAN. Ten patients (7-17 y) were treated. We investigated efficacy by testing motor function (6-minutes-Walk-Test (6-MWT), 3-min-Stair-Climb-Test (3-MSCT), The Bruininks-Oseretsky Test of Motor Proficiency (BOT2), cognitive function (Leiter-R), oligosaccharides in serum, urine and CSF and Tau- and GFA-protein in CSF. Results: Oligosaccharides: S-, U- and CSF-oligosaccharides decreased 88.6 % (CI -92.0 -85.2, p < 0.001), 54.1 % (CI -69.5- -38.7, p < 0,001), and 25.7 % (CI -44.3- -7.1, p < 0.05), respectively. Biomarkers: CSF-Tau- and GFA-protein decreased 15 %, p < 0.009) and 32.5, p < 0.001 respectively. Motor function: Improvements in 3MSCT (31 steps (CI 6.8-40.5, p < 0.01) and in 6MWT (60.4 m (CI -8.9 -51.1, NS) were achieved. Cognitive function: Improvement in the total Equivalence Age of 4 months (0.34) was achieved in the Leiter R test (CI -0.2-0.8, NS). Conclusions: These data suggest that rhLAMAN may be an encouraging new treatment for patients with alpha-mannosidosis.The study is designed to continue for a total of 18 months. Longer-term follow-up of patients in this study and the future placebo-controlled phase 3 trial are needed to provide greater support for the findings in this study.

U2 - 10.1007/s10545-013-9595-1

DO - 10.1007/s10545-013-9595-1

M3 - Journal article

C2 - 23494656

SN - 0141-8955

VL - 36

SP - 1015

EP - 1024

JO - Journal of Inherited Metabolic Disease

JF - Journal of Inherited Metabolic Disease

IS - 6

ER -

Enzyme replacement therapy for alpha-mannosidosis: 12 months follow-up of a single centre, randomised, multiple dose study

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this